News

Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple myeloma, revealing there are discrepancies in treatment initiation between the two patient populations and discussing the impact of these inequalities on clinical outcomes. The study was presented at…

The Multiple Myeloma Research Foundation (MMRF) has announced that its founder, Kathy Giusti, has been appointed faculty co-chair of the Harvard Business School (HBS) Kraft Precision Medicine Accelerator. Giusti, recently named by Fortune magazine as one of three business leaders who are changing medicine, is a former Harvard Business…

Researchers at the University of Louisville and collaborators from Japan and Austria have identified a protein called AF1q whose expression may predict the development of an aggressive form of multiple myeloma known as extramedullary disease (EMD). The findings were recently shown at the European Hematology Association’s 21st Congress in Copenhagen, Denmark, in a…

Researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) have showed that maintenance lenalidomide (marketed as Revlimid) following autologous hematopoietic stem cell (HSC) transplant improves the overall survival of multiple myeloma patients. The findings from the study “Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell…

In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase 1/2a clinical trial investigating MOR202 monotherapy in combination with lenalidomide (Len) and pomalidomide (Pom) plus dexamethasone (Dex) in 63 patients with relapsed/refractory multiple myeloma…

The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM) patients. The results of the trial were presented June 6 in Chicago at the 2016 Annual Meeting of the…

The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a…

An immune-based vaccine created by researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) is now moving to its third study. The new clinical trial will evaluate whether SurVaxM — a cancer vaccine that promotes immune response to the survivin molecule, a critical protein believed to maintain…

Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple myeloma (MM). The company, working with Merck Serono, was previously evaluating cilengitide in late-stage clinical trials as a potential treatment for glioblastoma, a brain cancer. Cilengitide is…

The International Myeloma Foundation (IMF), the largest organization focusing specifically on multiple myeloma (MM), is now alerting that a reportedly flawed document evaluating the cost of myeloma drugs can dangerously oversimplify a complex issue, limiting patients’ access to the best possible treatments. According to IMF, the report controversially concludes…